Wave Life Sciences (WVE) Q3 2024 earnings summary

Executive summary

• Achieved first-ever clinical RNA editing in humans with WVE-006 for AATD, demonstrating rapid and durable protein restoration and a favorable safety profile.

• Advanced clinical and preclinical GalNAc-conjugated RNA programs in AATD, DMD, HD, obesity, and cardiometabolic diseases, with supportive FDA feedback and regulatory designations.

• Positive interim data for WVE-N531 in DMD and WVE-003 in HD, both advancing toward potential accelerated approval, with key milestones expected in 2025.

• Expanded pipeline with new GalNAc RNA editing programs, aiming for five clinical programs by 2026.

• Strengthened financial position with a $230M public offering and extended cash runway into 2027.

Financial highlights

• Q3 2024 revenue was $(7.7)M, down from $49.2M in Q3 2023, due to lower collaboration revenue and a non-cash GSK revenue adjustment.

• R&D expenses rose to $41.2M from $31.6M year-over-year; G&A expenses increased to $15M from $13.1M.

• Net loss was $61.8M for Q3 2024, compared to net income of $7.3M in Q3 2023.

• Cash and equivalents were $310.9M as of September 30, 2024, with an additional $28.2M received in October.

• Cash runway expected to fund operations into 2027, excluding potential milestone payments.

Outlook and guidance

• Multi-dose data for WVE-006 in AATD and candidate selection for new GalNAc RNA editing programs expected in 2025.

• WVE-007 clinical trial for obesity to begin in Q1 2025.

• 48-week dystrophin data for WVE-N531 in DMD and FDA feedback on accelerated approval anticipated in Q1 2025.

• IND submission for WVE-003 in HD planned for 2H 2025, with a global phase II/III study in design.

• Expecting five GalNAc-conjugated clinical programs by 2026.